IGF1-LR3 1mg

IGF1-LR3 1mg — Long-Range Insulin-Like Growth Factor 1 Analog for Anabolic Research

IGF1-LR3 (Long R3 IGF-1) is a modified analog of insulin-like growth factor 1 (IGF-1) engineered for enhanced research utility. The peptide features two key modifications: a 13-amino-acid N-terminal extension and substitution of arginine for glutamic acid at position 3. These modifications dramatically reduce binding to IGF-binding proteins (IGFBPs), resulting in greatly increased bioavailability and a substantially extended functional half-life compared to native IGF-1, making IGF1-LR3 a workhorse compound in the growth hormone peptides research category.

Structural Modifications and Bioavailability

The Long R3 modifications fundamentally alter IGF-1 pharmacology by minimizing IGFBP sequestration, which normally limits the free bioactive fraction of native IGF-1. Research has documented that IGF1-LR3 maintains a substantially higher proportion of active free peptide in circulation, with a functional half-life of approximately 20-30 hours versus minutes for native IGF-1, allowing more practical research designs in animal models.

IGF-1 Receptor Pharmacology

Despite its modifications, IGF1-LR3 retains full agonist activity at the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase that activates downstream PI3K/Akt and Ras/MAPK signaling cascades. These pathways regulate cellular proliferation, differentiation, survival, protein synthesis, and metabolism across virtually every tissue type, giving IGF1-LR3 a broad research footprint.

Muscle and Connective Tissue Research

IGF1-LR3 has been extensively studied for its effects on muscle tissue. Research has documented increased muscle protein synthesis, satellite cell activation, myofiber hypertrophy, and enhanced muscle regeneration after injury in animal models. The peptide’s effects on connective tissue have also been characterized, with research demonstrating effects on tendon, ligament, and cartilage cell biology and matrix production.

Metabolic and Insulin Signaling Research

Given the structural and functional similarity of IGF-1 and insulin receptors, IGF1-LR3 has been used as a research tool for investigating metabolic signaling. Studies have examined effects on glucose uptake, cellular metabolism, and insulin-IGF-1 receptor crosstalk in various tissue and cell culture systems, providing investigators a controllable input for downstream pathway studies.

Neurological and Cognitive Research

IGF1-LR3 research extends to neurological applications, where the peptide has been studied for effects on neuronal survival, synaptic function, and neurogenesis. Animal models of neurodegeneration, traumatic brain injury, and cognitive aging have provided platforms for investigating IGF-1 signaling using this modified analog as an extended-duration research tool.

Comparison With Related GH-Axis Peptides

IGF1-LR3 sits downstream of growth hormone in the somatotropic axis, making it complementary to research peptides such as CJC 1295 + Ipamorelin and Sermorelin, which act upstream at the pituitary. Parallel investigations using IGF1-LR3 directly versus GH-axis stimulants help researchers dissect proximal versus distal effects of somatotropic signaling.

Quality, Storage, and Compliance

Each vial of IGF1-LR3 1mg is manufactured to 99%+ HPLC-verified purity and supplied as a sterile lyophilized powder. Store unreconstituted vials at -20°C; reconstituted material should be refrigerated at 2–8°C and used promptly. This IGF1-LR3 product is sold strictly for in-vitro laboratory research only — not for human consumption, diagnostic use, or any clinical application. Buyers must comply with all applicable provincial and federal regulations.